Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jonathan D.J. Wrigley is active.

Publication


Featured researches published by Jonathan D.J. Wrigley.


Bioorganic & Medicinal Chemistry Letters | 2003

A new series of potent benzodiazepine γ-secretase inhibitors

Ian Churcher; Kate Ashton; John W. Butcher; Earl E. Clarke; Timothy Harrison; Huw D. Lewis; Andrew Pate Owens; Martin Richard Teall; Susie Williams; Jonathan D.J. Wrigley

Abstract A new series of benzodiazepine-containing γ-secretase inhibitors with potential use in the treatment of Alzheimers disease is disclosed. Structure–activity relationships of the pendant hydrocinnamate side-chain which led to the preparation of highly potent inhibitors are described.


Journal of Biological Chemistry | 2005

Functional Overexpression of γ-Secretase Reveals Protease-independent Trafficking Functions and a Critical Role of Lipids for Protease Activity

Jonathan D.J. Wrigley; Irina Schurov; Emma J. Nunn; Agnes C. L. Martin; Earl E. Clarke; Semantha Ellis; Timothy P. Bonnert; Mark S. Shearman; Dirk Beher

Presenilins appear to form the active center of γ-secretase but require the presence of the integral membrane proteins nicastrin, anterior pharynx defective 1, and presenilin enhancer 2 for catalytic function. We have simultaneously overexpressed all of these polypeptides, and we demonstrate functional assembly of the enzyme complex, a substantial increase in enzyme activity, and binding of all components to a transition state analogue γ-secretase inhibitor. Co-localization of all components can be observed in the Golgi compartment, and further trafficking of the individual constituents seems to be dependent on functional assembly. Apart from its catalytic function, γ-secretase appears to play a role in the trafficking of the β-amyloid precursor protein, which was changed upon reconstitution of the enzyme but unaffected by pharmacological inhibition. Because the relative molecular mass and stoichiometry of the active enzyme complex remain elusive, we performed size exclusion chromatography of solubilized γ-secretase, which yielded evidence of a tetrameric form of the complex, yet almost completely abolished enzyme activity. γ-Secretase activity was reconstituted upon addition of an independent size exclusion chromatography fraction of lower molecular mass and nonproteinaceous nature, which could be replaced by a brain lipid extract. The same treatment was able to restore enzyme activity after immunoaffinity purification of the γ-secretase complex, demonstrating that lipids play a key role in preserving the catalytic activity of this protease. Furthermore, these data show that it is important to discriminate between intact, inactive γ-secretase complexes and the active form of the enzyme, indicating the care that must be taken in the study of γ-secretase.


Journal of Biological Chemistry | 2001

Pharmacological Knock-down of the Presenilin 1 Heterodimer by a Novel γ-Secretase Inhibitor IMPLICATIONS FOR PRESENILIN BIOLOGY

Dirk Beher; Jonathan D.J. Wrigley; Alan Nadin; Geneviève Evin; Colin L. Masters; Timothy Harrison; José L. Castro; Mark S. Shearman


Bioorganic & Medicinal Chemistry Letters | 2006

4-Substituted cyclohexyl sulfones as potent, orally active γ-secretase inhibitors

Ian Churcher; Dirk Beher; Jonathan D. Best; José L. Castro; Earl E. Clarke; Amy Gentry; Timothy Harrison; Laure Hitzel; Euan Kay; Sonia Kerrad; Huw D. Lewis; Pablo Morentin-Gutierrez; Russell J. Mortishire-Smith; Paul Joseph Oakley; Michael Reilly; Duncan E. Shaw; Mark S. Shearman; Martin Richard Teall; Susie Williams; Jonathan D.J. Wrigley


Bioorganic & Medicinal Chemistry Letters | 2005

Cyclic sulfamide γ-secretase inhibitors

Tim Sparey; Dirk Beher; Jonathan D. Best; Mirlinda Biba; José L. Castro; Earl E. Clarke; Joanne Clare Hannam; Timothy Harrison; Huw D. Lewis; Andrew Madin; Mark S. Shearman; Bindi Sohal; Nancy N. Tsou; Christopher J. Welch; Jonathan D.J. Wrigley


Bioorganic & Medicinal Chemistry Letters | 2003

High affinity, bioavailable 3-Amino-1,4-benzodiazepine-Based γ-Secretase inhibitors

Andrew Pate Owens; Alan Nadin; Adam C. Talbot; Earl E. Clarke; Timothy Harrison; Huw D. Lewis; Michael Reilly; Jonathan D.J. Wrigley; José L. Castro


Bioorganic & Medicinal Chemistry Letters | 2006

3-Substituted gem-cyclohexane sulfone based γ-secretase inhibitors for Alzheimer’s disease: Conformational analysis and biological activity

Richard Alexander Jelley; Jason Matthew Elliott; Karl R. Gibson; Timothy Harrison; Dirk Beher; Earl E. Clarke; Huw D. Lewis; Mark S. Shearman; Jonathan D.J. Wrigley


Bioorganic & Medicinal Chemistry Letters | 2006

The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer’s disease modifying agent

Nicholas Simon Stock; Benito Munoz; Jonathan D.J. Wrigley; Mark S. Shearman; Dirk Beher; James Peachey; Toni L. Williamson; Gretchen Bain; Weichao Chen; Xiaohui Jiang; René St-Jacques; Peppi Prasit


Archive | 2004

1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions

Dirk Beher; Michela Bettati; Ian Churcher; Benito Munzo; Petpiboon Prasit; Abdul Quddus; Nicholas Stock; Jonathan D.J. Wrigley


Archive | 2004

Treatment for alzheimer s disease and related conditions

Dirk Beher; Michela Bettati; Graham David Checksfield; Ian Churcher; Victoria Alexandra Doughty; Paul Joseph Oakley; Abdul Quddus; Martin Richard Teall; Jonathan D.J. Wrigley

Collaboration


Dive into the Jonathan D.J. Wrigley's collaboration.

Researchain Logo
Decentralizing Knowledge